The plaintiffs in the Xarelto lawsuit now have another reason to rejoice; a new study has exposed the dangers associated with taking this anticoagulant medication. The study, which was published in the Journal of the American Medical Association (JAMA)—Ophthalmology, has exposed the real dangers posed by the various side effects of rivaroxaban. Currently, the number of litigations that have been filed against this new-generation anticoagulant medication and its manufacturers are more than 4,000. The cases have been filed by patients who have suffered grave injuries as a result of the side effects of the medication.
The number of these cases continues to increase at a steady pace, as the public is enlightened on the increased risk of uncontrolled bleeding posed by the drug. To simplify the hearing process for these cases and make them as fair as possible, they were merged to form the Multidistrict Litigation number 2592 in the Eastern District of Louisiana, which is being overseen by Honorable Judge Eldon Fallon.
Lawyers handling these cases are continually searching for studies that show how risky or dangerous the drug can be to the consumers. This new study will serve as additional piece of evidence in these cases as it sheds light on how the use of this new-generation drug can lead to eye bleeding, specifically the Spontaneous Vitreous Hemorrhage form of eye hemorrhage. The findings of the study are backed by credible clinical findings; the doctors undertaking the study, doctors John C. Hwang and Judy Hun, observed three patients (suffering from this form of eye hemorrhage) they treated.
Based on their findings, the three patients had been taking conventional blood thinner drugs, such as warfarin, before they were advised to shift to Xarelto. Shortly after changing their drug regime, the three patients, aged between 70 and 89 years, suffered from eye bleeding, hence sought the help of these ophthalmologist. As such, the two ophthalmologists concluded that eye bleeding was a significant side effect of this product by Janssen Pharmaceuticals.
In a brief report, researches suggested that rivaroxaban increased the risk uncontrolled hemorrhages in its consumers. According to these researchers, the risk of suffering from such side effects was considerably higher in patients who had been using other anticoagulants such as warfarin, and then shifted to rivaroxaban. This occurs as the attorneys in the Xarelto court cases are searching for studies that can help their plaintiffs demonstrate to the court that the manufacturer actually released and marketed a dangerous and defective drug.